Advice
Following a full submission:
glycopyrronium inhalation powder (Seebri Breezhaler®) is accepted for use within NHS Scotland.
Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
In two phase III studies, glycopyrronium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks.
Download detailed advice138KB (PDF)
Medicine details
- Medicine name:
- glycopyrronium (Seebri Breezhaler)
- SMC ID:
- 829/12
- Indication:
- For a once daily maintenance bronchodilator treatment to relieve symptoms in patients with COPD.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 14 January 2013